View in EDS

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Authors: Chan A; Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia. Electronic address: arlenechan@me.com., Delaloge S; Institut Gustave Roussy, Villejuif, France., Holmes FA; Texas Oncology, Houston, TX, USA., Moy B; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Iwata H; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan., Harvey VJ; Auckland Hospital, Auckland, New Zealand., Robert NJ; Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA, USA., Silovski T; University Hospital For Tumors, University Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia., Gokmen E; Ege University Faculty of Medicine, Izmir, Turkey., von Minckwitz G; Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg, Germany., Ejlertsen B; Rigshospitalet, Copenhagen, Denmark., Chia SKL; BC Cancer Agency, Vancouver, BC, Canada., Mansi J; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK., Barrios CH; Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil., Gnant M; Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria., Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium., Gore I; Alabama Oncology, Birmingham, AL, USA., Smith J 2nd; Northwest Cancer Specialists, Vancouver, VA, USA., Harker G; Utah Cancer Specialists, Salt Lake City, UT, USA., Masuda N; National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka, Japan., Petrakova K; Masaryk Memorial Cancer Institute, Brno, Czech Republic., Zotano AG; Instituto Valenciano de Oncologia, València, Spain., Iannotti N; Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL, USA., Rodriguez G; South Texas Oncology and Hematology, San Antonio, TX, USA., Tassone P; Magna Graecia University, Catanzaro, Italy., Wong A; Puma Biotechnology, Los Angeles, CA, USA., Bryce R; Puma Biotechnology, Los Angeles, CA, USA., Ye Y; Puma Biotechnology, Los Angeles, CA, USA., Yao B; Puma Biotechnology, Los Angeles, CA, USA., Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
Corporate Authors: ExteNET Study Group
Source: The Lancet. Oncology [Lancet Oncol] 2016 Mar; Vol. 17 (3), pp. 367-377. Date of Electronic Publication: 2016 Feb 10.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 26874901
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chan+A%22">Chan A</searchLink>; Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia. Electronic address: arlenechan@me.com.<br /><searchLink fieldCode="AU" term="%22Delaloge+S%22">Delaloge S</searchLink>; Institut Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Holmes+FA%22">Holmes FA</searchLink>; Texas Oncology, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Moy+B%22">Moy B</searchLink>; Massachusetts General Hospital Cancer Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Iwata+H%22">Iwata H</searchLink>; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Harvey+VJ%22">Harvey VJ</searchLink>; Auckland Hospital, Auckland, New Zealand.<br /><searchLink fieldCode="AU" term="%22Robert+NJ%22">Robert NJ</searchLink>; Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA, USA.<br /><searchLink fieldCode="AU" term="%22Silovski+T%22">Silovski T</searchLink>; University Hospital For Tumors, University Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia.<br /><searchLink fieldCode="AU" term="%22Gokmen+E%22">Gokmen E</searchLink>; Ege University Faculty of Medicine, Izmir, Turkey.<br /><searchLink fieldCode="AU" term="%22von+Minckwitz+G%22">von Minckwitz G</searchLink>; Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg, Germany.<br /><searchLink fieldCode="AU" term="%22Ejlertsen+B%22">Ejlertsen B</searchLink>; Rigshospitalet, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Chia+SKL%22">Chia SKL</searchLink>; BC Cancer Agency, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Mansi+J%22">Mansi J</searchLink>; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Barrios+CH%22">Barrios CH</searchLink>; Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Gnant+M%22">Gnant M</searchLink>; Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Buyse+M%22">Buyse M</searchLink>; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.<br /><searchLink fieldCode="AU" term="%22Gore+I%22">Gore I</searchLink>; Alabama Oncology, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Smith+J+2nd%22">Smith J 2nd</searchLink>; Northwest Cancer Specialists, Vancouver, VA, USA.<br /><searchLink fieldCode="AU" term="%22Harker+G%22">Harker G</searchLink>; Utah Cancer Specialists, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Masuda+N%22">Masuda N</searchLink>; National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Petrakova+K%22">Petrakova K</searchLink>; Masaryk Memorial Cancer Institute, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Zotano+AG%22">Zotano AG</searchLink>; Instituto Valenciano de Oncologia, València, Spain.<br /><searchLink fieldCode="AU" term="%22Iannotti+N%22">Iannotti N</searchLink>; Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL, USA.<br /><searchLink fieldCode="AU" term="%22Rodriguez+G%22">Rodriguez G</searchLink>; South Texas Oncology and Hematology, San Antonio, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tassone+P%22">Tassone P</searchLink>; Magna Graecia University, Catanzaro, Italy.<br /><searchLink fieldCode="AU" term="%22Wong+A%22">Wong A</searchLink>; Puma Biotechnology, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Bryce+R%22">Bryce R</searchLink>; Puma Biotechnology, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ye+Y%22">Ye Y</searchLink>; Puma Biotechnology, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yao+B%22">Yao B</searchLink>; Puma Biotechnology, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Martin+M%22">Martin M</searchLink>; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ExteNET+Study+Group%22">ExteNET Study Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2016 Mar; Vol. 17 (3), pp. 367-377. <i>Date of Electronic Publication: </i>2016 Feb 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=26874901
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(15)00551-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 367
    Titles:
      – TitleFull: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chan A
      – PersonEntity:
          Name:
            NameFull: Delaloge S
      – PersonEntity:
          Name:
            NameFull: Holmes FA
      – PersonEntity:
          Name:
            NameFull: Moy B
      – PersonEntity:
          Name:
            NameFull: Iwata H
      – PersonEntity:
          Name:
            NameFull: Harvey VJ
      – PersonEntity:
          Name:
            NameFull: Robert NJ
      – PersonEntity:
          Name:
            NameFull: Silovski T
      – PersonEntity:
          Name:
            NameFull: Gokmen E
      – PersonEntity:
          Name:
            NameFull: von Minckwitz G
      – PersonEntity:
          Name:
            NameFull: Ejlertsen B
      – PersonEntity:
          Name:
            NameFull: Chia SKL
      – PersonEntity:
          Name:
            NameFull: Mansi J
      – PersonEntity:
          Name:
            NameFull: Barrios CH
      – PersonEntity:
          Name:
            NameFull: Gnant M
      – PersonEntity:
          Name:
            NameFull: Buyse M
      – PersonEntity:
          Name:
            NameFull: Gore I
      – PersonEntity:
          Name:
            NameFull: Smith J 2nd
      – PersonEntity:
          Name:
            NameFull: Harker G
      – PersonEntity:
          Name:
            NameFull: Masuda N
      – PersonEntity:
          Name:
            NameFull: Petrakova K
      – PersonEntity:
          Name:
            NameFull: Zotano AG
      – PersonEntity:
          Name:
            NameFull: Iannotti N
      – PersonEntity:
          Name:
            NameFull: Rodriguez G
      – PersonEntity:
          Name:
            NameFull: Tassone P
      – PersonEntity:
          Name:
            NameFull: Wong A
      – PersonEntity:
          Name:
            NameFull: Bryce R
      – PersonEntity:
          Name:
            NameFull: Ye Y
      – PersonEntity:
          Name:
            NameFull: Yao B
      – PersonEntity:
          Name:
            NameFull: Martin M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2016 Mar
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1